[BioS] Binex's CDMO Osong plant passes EMA inspection
Predicted impact: Medium
Osong CDMO plant passes EMA inspection, supporting European contract manufacturing prospects; no size given.
Binex바이넥스
053030 · KOSDAQ · ₩053030 · 바이넥스
₩6,070▼ ₩140 (2.25%)End-of-day · Oct 27, 2026 · End-of-day prices.
Price · 1Y −62.87%
- Market cap
- ₩198B
- Enterprise value
- ₩281B
- P/E
- —
- P/B
- 1.2×
- Dividend yield
- 0.0%
- ROE
- −18.2%
- Net margin
- −18.6%
Trailing 12 months from filed financial statements, as of H1 2026. Dividend yield: the 2025 dividend per share from the annual report ÷ today's price.
52-week range−63.9% from the high
₩5,500Today: ₩6,050 – ₩6,300₩16,800
Returns
- 1W−0.8%
- 1M+0.2%
- 3M−6.3%
- 6M−47.5%
- YTD−59.5%
- 1Y−62.9%
- Volume today
- 75,880
- 1.0× the 20-day average
- Traded today
- ₩465M
- Listed shares
- 32,684,188
- EPS (12 months)
- −₩895
- Earnings yield −14.8%
AI research · InitiationBinex: Revenue Holds Near ₩157B but Losses Widen in 2026 and Shares Fall 62.2% in a YearThe data presents a company with stable revenue of roughly ₩157B to ₩168B but a swing from near-breakeven in 2025 to a sizeable trailing loss.Read the full report →
Upcoming dates
Full calendar →🎁 Gift this stock
Send a friend ₩100,000 of paper money in this stock. They get it when they join.
Signals
Normal- BuzzNormalBuzz 45 of 100 (50 is a normal day for this stock).
- SentimentPositiveNews: Headline reports a regulatory inspection passed at a manufacturing plant. Community: 0 bullish, 0 bearish posts this week.
- MomentumFlat1.2% over the last month; the price is below its 20-day average.
- News impactSome2 news items and filings in two weeks; 0 rated high impact, 1 medium.
Signals describe activity, not recommendations. Not financial advice.
Binex stock overview
Binex (바이넥스, KRX: 053030) is listed on KOSDAQ, in the Biotech & Pharma sector. The company manufactures chemical pharmaceuticals at its Busan plant, including tablets, capsules, powders and eye drops, and sells them under its own brands. Its shares closed at ₩6,070 on Oct 27, 2026, down 2.25% on the day, giving it a market value of ₩198B.
Key facts
- Market cap
- ₩198B
- Sector
- Biotech & Pharma
- Latest price change
- −2.25%
- As of
- Oct 27, 2026
- Main business
- The company manufactures chemical pharmaceuticals at its Busan plant, including tablets, capsules, powders and eye drops, and sells them under its own brands.
Quick answers about Binex
- What does Binex do?
- The company manufactures chemical pharmaceuticals at its Busan plant, including tablets, capsules, powders and eye drops, and sells them under its own brands. Its main chemical products include a digestive remedy and a probiotic intestinal regulator, the latter described as its only original product. The company also provides biopharmaceutical contract development and manufacturing (CDMO) services, including cell line and process development, GMP production and protein analysis services, from its Songdo and Osong plants.
- What is the market cap of Binex?
- The market capitalisation of Binex was ₩198B at the close on Oct 27, 2026.
- Who are the largest shareholders of Binex?
- According to the latest official filings, the largest reported holders are The Able (10.76%, as of Oct 16, 2026); Samsung Asset Management (4.18%, as of May 7, 2026); National Pension Service (2.17%, as of Dec 31, 2025).
- When is the next earnings report from Binex?
- Korean companies rarely announce results dates in advance. Based on when Binex filed the same report in past years, its next 3q results is expected around Nov 14, 2026.
- Does the National Pension Service own Binex?
- Yes. The National Pension Service held 2.17% of Binex shares as of Dec 31, 2025.
Company profile
The company manufactures chemical pharmaceuticals at its Busan plant, including tablets, capsules, powders and eye drops, and sells them under its own brands. Its main chemical products include a digestive remedy and a probiotic intestinal regulator, the latter described as its only original product. The company also provides biopharmaceutical contract development and manufacturing (CDMO) services, including cell line and process development, GMP production and protein analysis services, from its Songdo and Osong plants.
Written by AI from the company's latest annual report.
- Korean name
- 바이넥스
- Sector
- Biotech & Pharma
- CEO
- 이혁종
- Founded
- Jun 1985
- Listed
- Aug 2001
- Listed shares
- 32,684,188
- Fiscal year ends
- Month 12
- Website
- www.bi-nex.co.kr
Similar companies
- Samsung Biologics207940 · ₩64T₩1,374,000−5.37%
- Celltrion068270 · ₩44T₩188,600−0.74%
- Alteogen196170 · ₩15T₩218,5000.00%
- Yuhan000100 · ₩5.9T₩80,000−2.08%
- SK biopharmaceuticals326030 · ₩5.9T₩74,900−1.19%
- HLB028300 · ₩5.3T₩39,900+1.66%
- Hanmi Pharm128940 · ₩4.5T₩350,500−0.57%
- SAM Chun Dang Pharm000250 · ₩4.4T₩187,600−0.69%
Recent news
Recent filings
See all- 5%+ holding reportOct 16, 2026
- Amended: Half-year report (Jun 2026)Oct 14, 2026
- Amended: Major sales or supply contractSep 30, 2026
- 5%+ holding reportSep 18, 2026
- Half-year report (Jun 2026)Aug 14, 2026
Titles in Korean until English translations are added.
Also known as: Binex / 바이넥스 / 053030 / KRX:053030
Source: KRX statistical information